BASF Launches Bio-Identical Collagen III at in-cosmetics Global

BASF is introducing two cosmetic actives at in-cosmetics Global in Paris this week: NeoHelix Regenerate, a precision peptide built on collagen-hybridizing peptide (CHP) technology from U.S. biotech startup 3Helix, and SkinNexus Collag3n, a recombinant bio-identical Collagen III fragment produced through vegan yeast fermentation by Bota Biosciences. In clinical study with female subjects aged 53 to 70, SkinNexus Collag3n produced measurable improvements in skin tonicity and a visible reduction in fine lines after four weeks, at a fraction of the concentration of a collagen market benchmark. NeoHelix Regenerate, in biopsy-confirmed studies run over 56 days, showed a 41% reduction in damaged collagen and a 65% increase in the skin's own hyaluronic acid, according to the BASF April 9 press release.

The Long-Standing Limits of Topical Collagen Science

Topical collagen has a credibility problem that is structural rather than marketing. Standard collagen molecules, whether derived from marine, bovine, or plant sources, are too large to penetrate the stratum corneum. Most hydrolyzed collagen peptides function primarily as humectants or film-formers at the surface rather than as structural contributors to the dermis. This is well-documented; the ingredient category is one of the most marketed-around concepts in skincare and one of the least understood.

The biology underneath the marketing is worth knowing. Young skin contains roughly 80% Collagen I and 15% Collagen III, according to published research in Skin Collagen Through the Lifestages (OAE Publishing, 2020). As the decades pass, Collagen III declines disproportionately. Research published in Regenerative Biomaterials (Oxford Academic, 2023) confirmed that the Collagen I/III ratio increases with aging as fibril diameter rises simultaneously, a structural shift that corresponds with decreased elasticity and the gradual loss of the fine-textured quality in younger dermis. Collagen III, in other words, is not a secondary player. It organizes fibril formation alongside Collagen I and is more closely associated with the papillary dermis, the layer closest to the skin surface where anti-aging interventions matter most.

The challenge until now has been that no topical ingredient has been able to specifically address Collagen III depletion with a verified biomimetic mechanism and clinical data. Both BASF launches attempt to answer that gap, from two different directions.

How Does NeoHelix Regenerate Target Damaged Collagen Without Affecting Healthy Fibers?

NeoHelix Regenerate uses single-stranded collagen-like peptides to exploit a precise structural difference: damaged collagen loses its characteristic triple-helix conformation, while healthy collagen retains it. The CHP peptides bind selectively to unfolded collagen strands, leaving intact fibers unchanged and concentrating the active where repair is needed.

This mechanism is borrowed from diagnostic medicine. 3Helix's Collagen Hybridizing Peptide platform was originally developed to localize and bind to areas of collagen damage in clinical research. Adapting it for topical cosmetics required engineering the peptides for skin compatibility and formulation stability. In the 56-day biopsy study, NeoHelix Regenerate produced a 41% reduction in damaged collagen and a 65% increase in endogenous hyaluronic acid. A separate in vivo study confirmed improvements in skin thickness, tonicity, and forehead wrinkle appearance, with the ingredient outperforming a comparative peptide benchmark across all measured parameters. "By working with the skin's own biology, we are moving from traditional collagen-support claims to more advanced renewal and preservation across multiple levels," said Lucilene Veira Nunes, Business Management at BASF Beauty Care Solutions, in the April 9 press release. For those comparing where this fits in a routine, the mechanism is fundamentally different from signaling peptides covered in SkinCareful's guide to peptide serum science. CHP peptides do not signal fibroblasts; they physically bind to existing damaged structures.

SkinNexus Collag3n takes a different route. Rather than targeting damaged collagen, it supplies the skin's extracellular matrix with a recombinant Collagen III fragment that is sequence-identical to human Collagen III. The manufacturing process, developed by Bota Biosciences using their SAION AI platform for end-to-end biomanufacturing optimization, uses vegan yeast fermentation, producing no animal-derived byproducts. The result is an ingredient that is analytically distinct from marine or bovine hydrolysates and from short collagen peptide fractions. In a 3D dermis model, SkinNexus Collag3n increased Collagen I by 48%, Collagen III by 82%, and Collagen V by 71% relative to control. In the four-week clinical study with subjects aged 53 to 70, it delivered measurable improvements in tonicity, sagging appearance, and fine lines, while outperforming a competitor collagen ingredient present at ten times the concentration. This positions it alongside the regenerative ingredient class SkinCareful has covered in relation to PDRN's cellular repair mechanism, with a different molecular approach and similar clinical ambition.

When Will Consumers See These Ingredients in Products?

NeoHelix Regenerate and SkinNexus Collag3n are ingredient-level launches, directed at cosmetic formulators rather than consumers. BASF Beauty Care Solutions will present both actives through April 16 in Hall 7 at the Paris Expo Porte de Versailles, and both are available for licensing now. Finished consumer products incorporating either ingredient would follow a standard formulation and stability testing cycle, typically 12 to 24 months from ingredient adoption to retail shelf, depending on the brand and regulatory market. BASF has not announced branded formulation partnerships to date.

What makes these launches significant for consumers tracking where skincare science is heading: they represent two technically credible approaches to a category that has been dominated by marketing. A peptide that binds selectively to damaged collagen and a bio-identical Collagen III produced by yeast are not the same as a hydrolyzed collagen serum. The clinical data confirms the distinction.